Jingna Wu

机构：Harbin Medical University, Meizhou City People's Hospital, Third Affiliated Hospital of Harbin Medical University

发表论文 10 篇 · 总被引 25 次 · h-index 3

代表论文

• Pretreatment System Inflammation Response Index (SIRI) is a Valuable Marker for Evaluating the Efficacy of Neoadjuvant Therapy in Breast Cancer Patients (2024 · International Journal of General Medicine · 被引 10)
• Changing Patterns in Clinicopathological Characteristics of Breast Cancer and Prevalence of BRCA Mutations: Analysis in a Rural Area of Southern China (2021 · International Journal of General Medicine · 被引 8)
• 1562MO Effectiveness of COVID-19 vaccination in cancer patients: A nationwide Veterans Affairs study (2021 · Annals of Oncology · 被引 3)
• The safety, tolerability, and efficacy of BRY812 in patients with advanced solid tumors: Preliminary results from the phase I clinical study. (2025 · Journal of Clinical Oncology · 被引 2)
• Association of LIV-1 expression with clinical efficacy in patients with advanced breast cancers treated with BRY812. (2025 · Journal of Clinical Oncology · 被引 1)
• A basement membrane-related signature for prognosis and immunotherapy benefit in bladder cancer based on machine learning (2024 · Discover Oncology · 被引 1)